- Home
- CTAA vs MNOV Comparison
CTAA vs MNOV Comparison
Compare CTAA & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTAA | MNOV |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 137.8M |
| IPO Year | 2026 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CTAA | MNOV |
|---|---|---|
| Price | $10.10 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 106.4K | ★ 786.3K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $9.88 | $1.17 |
| 52 Week High | $10.01 | $3.90 |
Technical Indicators
Market Signals| Indicator | CTAA | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 36.26 |
| Support Level | $9.91 | $1.29 |
| Resistance Level | N/A | $1.48 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 100.00 | 1.55 |
Price Performance
Historical ComparisonAbout CTAA ClearThink 1 Acquisition Corp. Class A Ordinary Shares
ClearThink 1 Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.